FDA releases denial letters for unapproved drugs, a step toward transparency The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Know Your Source: Protecting Patients from Unsafe Drugs FDA FDA moves toward easing restrictions on certain peptides BioPharma Dive Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law